Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives. Quick Links Investor Presentation Responsibility News Portfolio Responsibility Report Annual Reports Leadership Governance SEC Filings Latest Press Releases January 15, 2025 Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes January 13, 2025 Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference January 8, 2025 Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) All press releases Latest Events Jan 13 2025 Jan 13 2025 J. P .Morgan Healthcare Conference Click here for Webcast Dec 12 2024 Dec 12 2024 Incyte Data Highlights from ASH 2024 Click here for Webcast All events
